Chinese Journal of Pharmacovigilance ›› 2021, Vol. 18 ›› Issue (3): 240-244.
DOI: 10.19803/j.1672-8629.2021.03.07
Previous Articles Next Articles
LI Zhaohui
Online:
2021-03-15
Published:
2021-04-06
CLC Number:
LI Zhaohui. Thoughts on Promoting the Implementation of Licensed Pharmacist System in the New Era[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 240-244.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.2021.03.07
[1] The State Council The People's Republic of China.“Healthy China 2030”planning outline[EB/OL].(2016-10-25) [2020-08-30].http://www.gov.cn/zhengce/2016-10/25/content_5124174. htm. [2] National Medical Products Administration. Notice on issuing the provisions on the professional qualification system for licensed pharmacists and the implementation measures for the professional qualification examination for licensed pharmacists[EB/OL].(2019-03-20) [2020-08-30].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20190320161601446. html. [3] Pan YN, Chen XF, Yu HZ.Thoughts on the current situation of my country's vocational qualification system[J].Chemical Times(化工时刊), 2019, 33(9): 41-43. [4] Cao XQ.Comparative study on china and british occupation qualification certificate system[D].Yunnan:Yunnan University, 2017. [5] Li ZH. Comparison of the professional qualification examination system between law and licensed pharmacist[N].Medicine Economic Reporter(医药经济报), 2020-07-06 (004). [6] Li ZH. Tracking the legalization process of licensed pharmacist qualification system[N].Medicine Economic Reporter (医药经济报), 2020-07-02 (005). [7] Li ZH. Overview of the development of pharmacist practice[N]. Medicine Economic Reporter(医药经济报), 2020-04-09 (005). [8] National Medical Products Administration. Notice on carrying out the rectification work of licensed pharmacists in pharmaceutical retail enterprises[EB/OL].(2019-03-19) [2020-08-30].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20190319135901873. html. [9] The National People's Congress of the People's Republic of China. Drug administration law of the people's republic of china[EB/OL].(2019-08-26) [2020-08-30].http://www.npc.gov.cn/npc/c30834/201908/26a6b28dd83546d79d17f90c62e59461. shtml. [10] The State Council The People's Republic of China. Regulations for the implementation of the drug administration law of the people's republic of china[EB/0L].(2005-08-02) [2020-08-30].. Regulations for the implementation of the drug administration law of the people's republic of china[EB/0L].(2005-08-02) [2020-08-30].http://www.gov.cn/banshi/2005-08/02/content_19275. htm. [11] National Medical Products Administration. Decision of the State Food and Drug Administration on the revision of the "Pharmaceutical Business Quality Management Regulations"[EB/OL].(2016-07-20) [2020-08-30].https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20160720093001180. html. [12] Li ZH. Significance of implementing alicensed pharmacist qualification system[N]. Medicine Economic Reporter(医药经济报), 2020-04-16 (005). [13] Ban LJ, Li ZH, Li RF.Analysis of the staffing levels and use of licensed pharmacists in retail pharmacies in yunnan province[J].China Pharmaceuticals(中国药业), 2019, 28(8):76-78. [14] Li ZH. Explanation of the registration system of licensed pharmacists[N]. Medicine Economic Reporter(医药经济报), 2020-07-30 (005). [15] China Food and Drug Net. The registration of licensed pharmacists has been implemented nationwide and the entire process online for 12 years[EB/OL].(2020-07-23) [2020-08-30].http://www.cnpharm. com/c/2020-07-23/744113. shtml. [16] Certification Center for Licensed Pharmacist of National Medical Products Administration. Registration status of national licensed pharmacists in July 2020[EB/OL].(2020-08-07) [2020-08-30].http://www.cqlp.org/info/link.aspx?id=4212&page=1. [17] International Pharmaceutical Federation-(FIP)2017. Pharmacy at glance-(2015-2017)[M].The Hague, The Netherlands: International Pharmaceutical Federation, 2017: 2. [18] National Medical Products Administration.2019 Annual report on drug supervision statistics[EB/OL].(2020-08-05) [2020-08-30].https://www.nmpa.gov.cn/zwgk/tjxx/tjnb/20200805110116109.html. [19] Wang XD. "The most beautiful" force guards drug safety[N].China Medical News(中国医药报), 2019-12-13 (01). [20] Tang ZJ,Ye H. The role of licensed pharmacists is not single[N].Medicine Economic Reporter(医药经济报), 2020-04-27 (004). [21] Li HY, Yang CP, Jin HT.Recent research progress in mechanism of Liver injury induced by common drugs[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(12): 750-756. [22] Sun J, Yu DD, Li M, et al.Analysis of current abuse among drug abusers in china[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2020,17(1): 37-43, 55. [23] National Medical Products Administration. Publicly solicit opinions on the "notice on regulating the provision and use of licensed pharmacists in pharmaceutical retail enterprises (Draft for Solicitation of Comments)"[EB/OL].(2020-08-17)[2020-08-30].https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20200817163533130. html. |
[1] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[2] | MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172. |
[3] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
[4] | GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5. |
[5] | MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe. Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32. |
[6] | LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101. |
[7] | TIAN Chunhua, WU Guizhi. Implementation of periodic benefit risk evaluation reports in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384. |
[8] | ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang. Post-marketing active monitoring of medical devices under vigilance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390. |
[9] | PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263. |
[10] | WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089. |
[11] | JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094. |
[12] | LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098. |
[13] | XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970. |
[14] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
[15] | SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||